Skip to main content

Advertisement

Contact Sven de Vos

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Contact corresponding author